Close Menu

NEW YORK – Novacyt announced Wednesday it is partnering with AstraZeneca, GlaxoSmithKline, and the University of Cambridge to increase SARS-CoV-2 testing in the United Kingdom.

The collaboration is in support of a so-called "five pillar plan" from the UK to increase testing for the coronavirus. 

AstraZeneca, GSK, and Cambridge are setting up a new testing laboratory at the university to provide high-throughput screening for SARS-CoV-2 testing. The lab will also explore using alternative chemical reagents for diagnostic tests to alleviate current supply shortages.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.